EDITAS MEDICINE INC (EDIT)
US28106W1036 - Common Stock
Overall EDIT gets a fundamental rating of 3 out of 10. We evaluated EDIT against 587 industry peers in the Biotechnology industry. The financial health of EDIT is average, but there are quite some concerns on its profitability. EDIT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EDIT had negative earnings in the past year.
In the past year EDIT has reported a negative cash flow from operations.
In the past 5 years EDIT always reported negative net income.
EDIT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -30.70%, EDIT is in the better half of the industry, outperforming 71.79% of the companies in the same industry.
EDIT has a Return On Equity of -43.89%. This is in the better half of the industry: EDIT outperforms 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -43.89% | ||
| ROIC | N/A |
ROA(3y)-33.99%
ROA(5y)-29.7%
ROE(3y)-46.59%
ROE(5y)-44.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for EDIT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
EDIT has more shares outstanding than it did 1 year ago.
EDIT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EDIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EDIT has an Altman-Z score of -1.88. This is a bad value and indicates that EDIT is not financially healthy and even has some risk of bankruptcy.
EDIT's Altman-Z score of -1.88 is in line compared to the rest of the industry. EDIT outperforms 49.91% of its industry peers.
EDIT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.88 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
A Current Ratio of 5.39 indicates that EDIT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.39, EDIT is in line with its industry, outperforming 57.27% of the companies in the same industry.
EDIT has a Quick Ratio of 5.39. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.39, EDIT is in line with its industry, outperforming 58.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.39 | ||
| Quick Ratio | 5.39 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.14% over the past year.
Looking at the last year, EDIT shows a very strong growth in Revenue. The Revenue has grown by 296.39%.
The Revenue has been growing by 19.59% on average over the past years. This is quite good.
EPS 1Y (TTM)36.14%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q73.86%
Revenue 1Y (TTM)296.39%
Revenue growth 3Y-4.86%
Revenue growth 5Y19.59%
Revenue growth Q2Q818.18%
3.2 Future
The Earnings Per Share is expected to grow by 8.52% on average over the next years. This is quite good.
EDIT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.28% yearly.
EPS Next Y-31.84%
EPS Next 2Y-15.34%
EPS Next 3Y-11.84%
EPS Next 5Y8.52%
Revenue Next Year29.03%
Revenue Next 2Y1.43%
Revenue Next 3Y39.08%
Revenue Next 5Y61.28%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDIT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as EDIT's earnings are expected to decrease with -11.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.34%
EPS Next 3Y-11.84%
5. Dividend
5.1 Amount
No dividends for EDIT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EDITAS MEDICINE INC
NASDAQ:EDIT (5/8/2024, 4:22:26 PM)
After market: 5.1 +0.07 (+1.39%)5.03
-0.65 (-11.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap413.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -43.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.39 | ||
| Quick Ratio | 5.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.14%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-31.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)296.39%
Revenue growth 3Y-4.86%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y